JP6796372B2 - 神経障害および精神障害の行動症状を治療する方法 - Google Patents

神経障害および精神障害の行動症状を治療する方法 Download PDF

Info

Publication number
JP6796372B2
JP6796372B2 JP2014551323A JP2014551323A JP6796372B2 JP 6796372 B2 JP6796372 B2 JP 6796372B2 JP 2014551323 A JP2014551323 A JP 2014551323A JP 2014551323 A JP2014551323 A JP 2014551323A JP 6796372 B2 JP6796372 B2 JP 6796372B2
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
administration
weeks
intake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014551323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503586A (ja
JP2015503586A5 (enExample
Inventor
ジョーン エム． ファロン
ジョーン エム． ファロン
マシュー エフ． ハイル
マシュー エフ． ハイル
ジェイムズ シゲチ
ジェイムズ シゲチ
ケニス ナナス
ケニス ナナス
ジェイムズ ジェイ． ファロン
ジェイムズ ジェイ． ファロン
Original Assignee
キュアマーク， リミテッド ライアビリティ カンパニー
キュアマーク， リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュアマーク， リミテッド ライアビリティ カンパニー, キュアマーク， リミテッド ライアビリティ カンパニー filed Critical キュアマーク， リミテッド ライアビリティ カンパニー
Publication of JP2015503586A publication Critical patent/JP2015503586A/ja
Publication of JP2015503586A5 publication Critical patent/JP2015503586A5/ja
Application granted granted Critical
Publication of JP6796372B2 publication Critical patent/JP6796372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Closures For Containers (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2014551323A 2012-01-03 2013-01-03 神経障害および精神障害の行動症状を治療する方法 Active JP6796372B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261582813P 2012-01-03 2012-01-03
US61/582,813 2012-01-03
US201261600110P 2012-02-17 2012-02-17
US61/600,110 2012-02-17
PCT/US2013/020183 WO2013103746A1 (en) 2012-01-03 2013-01-03 Methods of treating behavioral symptoms of neurological and mental disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018153357A Division JP6810724B2 (ja) 2012-01-03 2018-08-17 神経障害および精神障害の行動症状を治療する方法

Publications (3)

Publication Number Publication Date
JP2015503586A JP2015503586A (ja) 2015-02-02
JP2015503586A5 JP2015503586A5 (enExample) 2016-02-04
JP6796372B2 true JP6796372B2 (ja) 2020-12-09

Family

ID=48745413

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014551323A Active JP6796372B2 (ja) 2012-01-03 2013-01-03 神経障害および精神障害の行動症状を治療する方法
JP2018153357A Active JP6810724B2 (ja) 2012-01-03 2018-08-17 神経障害および精神障害の行動症状を治療する方法
JP2020166691A Pending JP2021001222A (ja) 2012-01-03 2020-10-01 神経障害および精神障害の行動症状を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018153357A Active JP6810724B2 (ja) 2012-01-03 2018-08-17 神経障害および精神障害の行動症状を治療する方法
JP2020166691A Pending JP2021001222A (ja) 2012-01-03 2020-10-01 神経障害および精神障害の行動症状を治療する方法

Country Status (16)

Country Link
US (3) US20130224172A1 (enExample)
EP (1) EP2800581B1 (enExample)
JP (3) JP6796372B2 (enExample)
KR (3) KR20190109564A (enExample)
CN (2) CN104144698A (enExample)
AU (2) AU2013206890B2 (enExample)
BR (1) BR112014016557A8 (enExample)
CA (1) CA2862403C (enExample)
DK (1) DK2800581T3 (enExample)
GB (1) GB2511713B (enExample)
HK (1) HK1257360A1 (enExample)
IL (1) IL233372B (enExample)
MX (2) MX363096B (enExample)
NZ (2) NZ737957A (enExample)
RU (1) RU2654230C2 (enExample)
WO (1) WO2013103746A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
AU2016247301A1 (en) * 2015-04-14 2017-10-26 Steven Hoffman Compositions and methods for treating autism
CN105213433A (zh) * 2015-11-06 2016-01-06 王益超 一种用于治疗孤独症、复发性流产和不孕症的组合物
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11547707B2 (en) * 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US20210043106A1 (en) * 2019-08-08 2021-02-11 COGNITIVEBOTICS Technologies Pvt. Ltd. Technology based learning platform for persons having autism
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN112347257B (zh) * 2020-11-11 2024-07-09 北京嘉和海森健康科技有限公司 一种患者症状口语化标准化方法和装置
WO2023201358A2 (en) * 2022-04-15 2023-10-19 AEON Biopharma, Inc. Neurotoxin compositions for use in regulating brain temperature

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6534063B1 (en) * 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
US6251478B1 (en) 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
US6261613B1 (en) 2000-02-15 2001-07-17 General Mills, Inc. Refrigerated and shelf-stable bakery dough products
US6399114B2 (en) * 2000-05-26 2002-06-04 C & D Foreman, Inc. Nutritional system for nervous system disorders
US6660831B2 (en) 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
DE10065123B4 (de) * 2000-12-28 2012-12-20 Robert Bosch Gmbh Verfahren zur Steuerung einer Diagnose eines Katalysators im Abgas eines Verbrennungsmotors
AU2002364750A1 (en) * 2001-12-14 2003-06-30 Solvay Pharmaceuticals Gmbh Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
US20060115467A1 (en) * 2004-12-01 2006-06-01 Pangborn Jon B Compositions and methods for the treatment of autism
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
JP5914357B2 (ja) * 2010-01-15 2016-05-11 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 自閉症の治療のための化合物

Also Published As

Publication number Publication date
GB201411821D0 (en) 2014-08-13
NZ734194A (en) 2021-02-26
AU2017232048A1 (en) 2017-10-12
MX2019002669A (es) 2019-05-30
GB2511713A (en) 2014-09-10
AU2017232048B2 (en) 2019-05-02
IL233372B (en) 2019-09-26
MX363096B (es) 2019-03-08
IL233372A0 (en) 2014-08-31
MX2014008156A (es) 2015-04-13
HK1257360A1 (zh) 2019-10-18
US20210162024A1 (en) 2021-06-03
RU2654230C2 (ru) 2018-05-17
JP2015503586A (ja) 2015-02-02
KR20200113029A (ko) 2020-10-05
EP2800581A4 (en) 2015-08-12
WO2013103746A1 (en) 2013-07-11
NZ716627A (en) 2017-08-25
US20130224172A1 (en) 2013-08-29
HK1201731A1 (en) 2015-09-11
EP2800581B1 (en) 2024-05-22
CN104144698A (zh) 2014-11-12
NZ737957A (en) 2021-07-30
RU2014130165A (ru) 2016-02-27
JP6810724B2 (ja) 2021-01-06
US20260069667A1 (en) 2026-03-12
DK2800581T3 (da) 2024-06-17
CA2862403C (en) 2022-08-09
JP2019006788A (ja) 2019-01-17
EP2800581A1 (en) 2014-11-12
BR112014016557A8 (pt) 2017-07-04
CA2862403A1 (en) 2013-07-11
JP2021001222A (ja) 2021-01-07
KR20140107665A (ko) 2014-09-04
AU2013206890A1 (en) 2014-07-24
BR112014016557A2 (pt) 2017-06-13
KR102315761B1 (ko) 2021-10-20
AU2013206890B2 (en) 2017-09-28
GB2511713B (en) 2020-03-04
KR20190109564A (ko) 2019-09-25
CN108578684A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
JP6810724B2 (ja) 神経障害および精神障害の行動症状を治療する方法
NZ738140A (en) Door closure
JP6234965B2 (ja) 酵素送達システムならびに調製方法および使用方法
Munasinghe et al. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial
JP2015503586A5 (enExample)
EP3324757A1 (en) Allergy preventing dosage controlled food packets
Arif et al. Effect of different nutritional interventions in children with autism spectrum disorder: A systematic review
NZ738140B2 (en) Tau-binding antibodies
NZ734194B2 (en) Methods of treating behavioral symptoms of neurological and mental disorders
Washnieski Gluten-free and casein-free diets as a form of alternative treatment for autism spectrum disorders
Pelton Rapamycin: mTOR, Autophagy and Treating mTOR Syndrome
Sharma Role of Multi-Cereal in Nutritional Strategies in Children with Autism
Shelton Pre-conception and Prenatal Strategies Towards Prevention of Autism Spectrum Disorder (ASD), and Holistic Nutritional Practices for Parenting the Child with ASD.
Mak et al. and Healthy Ageing
FOOD Efficacy and safety of gluten-free and casein-free diets proposed in children presenting with pervasive developmental disorders (autism and related syndromes)
Cordas Toxicology: Exploring the Concept of Exogenous and Endogenous Toxins
Gordon An Investigation Into the Effects of Micronutrients on Mood and Behaviour in Children with Attention-deficit/hyperactivity Disorder (ADHD): A Pilot Study Using a Single Case ABABA Design with Six-month Follow-up: a Thesis Submitted in Partial Fulfilment of the Requirements for the Degree of Doctor of Philosophy in Psychology in the University of Canterbury, Psychology Department, Christchurch, New Zealand
Lewis Dietary Intervention for the Treatment of Autism: Why Implement a Gluten and Casein Free Diet?
Rona A Natural Approach to ADHD: Drug-free Strategies to Restore Mental Health
JP2019142937A (ja) 実行機能を増強するための２５−ヒドロキシビタミンｄ３の使用
Schachter et al. What Your Doctor May Not Tell You About (TM): Alzheimer's Disease: The Breakthrough Integrative Approach for Effective Treatment
This Are all harmful forces that wreak havoc on the brain and cause damage to the rest of the body.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140806

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180817

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20180817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180817

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180905

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20180906

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20181005

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20181010

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190221

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190403

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190605

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190708

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20190902

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20190902

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20190902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200302

C54 Written response to inquiry

Free format text: JAPANESE INTERMEDIATE CODE: C54

Effective date: 20200302

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20200916

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201005

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20201112

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201116

R150 Certificate of patent or registration of utility model

Ref document number: 6796372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250